The decision to terminate a pregnancy should not be made because of noninvasive DNA high-risk, a separate screening test. Noninvasive DNA is a means of screening for Down syndrome in the fetus through fetal free DNA in the peripheral blood of the pregnant woman, which is much more accurate than Down’s syndrome, but there are uncertainties. The accuracy of non-invasive DNA on chromosomes 13 and 18 and sex chromosomes is less accurate, so non-invasive high-risk does not confirm that the fetus has a hereditary disease. The high risk of non-invasive DNA should be taken with a high degree of caution, as it represents a higher risk of the fetus having a hereditary disease. Pregnant women need to consult their attending physician for advice and undergo amniocentesis in the second trimester of pregnancy to further confirm the diagnosis. Although amniocentesis carries a certain risk of miscarriage, it is a direct extraction of amniotic fluid to analyze the baby’s chromosomes, which is highly accurate and has clinical reference significance. If the conclusion of amniocentesis confirms abnormal development of the fetus, schedule a time for termination of pregnancy as soon as possible under the advice of your doctor.